Streetbeat News

Revenues

FTHM

Fathom Holdings (NASDAQ:FTHM) has been analyzed by 6 analysts over the last three months, showing a shift towards more bullish ratings despite a decrease in the average 12-month price target from $6.08 to $4.33. Analysts from firms like DA Davidson, Stephens & Co., Roth MKM, and B. Riley Securities have lowered their price targets, reflecting a cautious outlook on the company's financial performance, which includes a revenue decline of -11.23% and a net margin of -11.39%. Despite these challenges, Fathom Holdings's ROE of -15.2% indicates effective use of equity capital.

Portfolio Pulse from Benzinga Insights

May 13, 2024 | 8:00 pm

INVH

Invitation Homes (NYSE:INVH) has been the subject of diverse analyst ratings over the past three months, with a shift towards a more neutral stance in the last 30 days. The average 12-month price target for INVH has been raised to $37.75, reflecting a 2.72% increase from the previous target of $36.75. Analysts from firms like Keefe, Bruyette & Woods, Raymond James, and Citigroup have updated their ratings and price targets, indicating varying levels of performance expectations for the company. Invitation Homes, owning over 84,000 single-family rental homes, shows strong financial indicators such as a 3.48% revenue growth rate, a net margin of 22.0%, and an ROE of 1.4%, positioning it well in the real estate sector.

Portfolio Pulse from Benzinga Insights

May 13, 2024 | 8:00 pm

RSI

Rush Street Interactive (NYSE:RSI) has seen a diverse range of analyst ratings over the last three months, with recent updates showing a positive trend in price targets. Analysts have raised their price targets, reflecting an average increase of 19.43% from the previous average to $8.36. The company's financial performance shows a notable revenue growth of 33.92% over a three-month period, despite challenges in profitability and efficiency as indicated by its net margin, ROE, and ROA.

Portfolio Pulse from Benzinga Insights

May 13, 2024 | 8:00 pm

CHRD

Chord Energy (NASDAQ:CHRD) has received mixed analyst ratings over the past three months, with an overall bullish sentiment. The average 12-month price target for CHRD has been raised to $212.9, indicating a 5.14% increase from the previous target of $202.50. Analysts from firms like Mizuho, RBC Capital, Piper Sandler, Truist Securities, and Stifel have adjusted their ratings and price targets, reflecting changes in market conditions and company performance. Chord Energy's financials show strong revenue growth, net margin, ROE, and ROA, positioning it favorably compared to industry peers.

Portfolio Pulse from Benzinga Insights

May 13, 2024 | 7:01 pm

CRGY

Crescent Energy (NYSE:CRGY) has received mixed analyst ratings over the past three months, with a downward trend in the 12-month price target to $16.6 from $17.25. Analyst actions include both upgrades and downgrades, reflecting varying perspectives on the company's performance and market conditions. Crescent Energy's financial performance shows strong revenue growth but challenges in profitability and high debt levels.

Portfolio Pulse from Benzinga Insights

May 13, 2024 | 7:00 pm

PI

Analysts have recently updated their ratings and price targets for Impinj (NASDAQ:PI), showing a positive shift in sentiment. The average 12-month price target has increased to $151.45, with a high estimate of $200.00 and a low of $125.00, marking a significant rise from the previous average of $128.50. This change reflects a more bullish outlook from analysts, with recent ratings upgrades and raised price targets from firms such as Jefferies, Goldman Sachs, and Susquehanna. Despite facing revenue challenges and a high debt-to-equity ratio, Impinj's strong net margin and ROE indicate solid profitability and effective equity capital utilization.

Portfolio Pulse from Benzinga Insights

May 13, 2024 | 7:00 pm

CTOS

Custom Truck One Source (CTOS) has received mixed analyst ratings over the past three months, with a current average price target of $8.00, down 7.73% from $8.67. Analysts from firms including Oppenheimer, JP Morgan, Baird, and DA Davidson have adjusted their ratings and price targets, reflecting a nuanced view of the company's performance and market position. Despite the diverse ratings, the company faces challenges such as a decline in revenue, below-average net margin, ROE, and ROA, alongside a high debt-to-equity ratio.

Portfolio Pulse from Benzinga Insights

May 13, 2024 | 7:00 pm

CMCSA

12 financial analysts have provided mixed ratings for Comcast (NASDAQ:CMCSA), with a recent shift towards a more cautious outlook. The average 12-month price target has been adjusted to $47.85, marking a 3.82% decrease from the previous target. Analyst actions include maintaining, lowering, and announcing ratings, reflecting changing market dynamics and Comcast's performance. Comcast's financial health indicators such as market capitalization, revenue growth, net margin, ROE, and ROA are highlighted, alongside its business components including the core cable business, NBCUniversal, and Sky.

Portfolio Pulse from Benzinga Insights

May 13, 2024 | 7:00 pm

LSCC

Lattice Semiconductor (NASDAQ:LSCC) received mixed analyst ratings, with an updated average 12-month price target of $82.29, reflecting a 7.27% increase from the previous target. The company's financial health shows challenges in revenue growth and ROE, but strengths in net margin, ROA, and debt management. Analysts from firms like Jefferies, B of A Securities, and Baird have adjusted their ratings and price targets, indicating a positive outlook on LSCC's performance.

Portfolio Pulse from Benzinga Insights

May 13, 2024 | 6:01 pm

PACB

Pacific Biosciences (NASDAQ:PACB) has been analyzed by 10 analysts, showing a shift towards a more cautious outlook with recent ratings leaning towards neutral. The average 12-month price target has been significantly lowered from $8.90 to $4.4, reflecting a 50.56% decline and indicating a bearish sentiment. Analysts from firms like Piper Sandler, Barclays, and Goldman Sachs have adjusted their price targets downwards in response to market dynamics and company performance. Despite positive revenue growth of 113.35% as of December 31, 2023, Pacific Biosciences faces challenges in profitability and efficient capital utilization, with a net margin of -140.55% and ROE of -11.2%.

Portfolio Pulse from Benzinga Insights

May 13, 2024 | 6:00 pm